IDiyas

For the Inventor, By the Inventor

Somerset, NJ, United States of America

Keith C Silverman

USPTO Granted Patents = 14

Average Co-Inventor Count = 6.5

ph-index = 4

Forward Citations = 64(Granted Patents)


Company Filing History:

goldMedal14 out of 4,770 
 
Merck + Co., Inc.
 patents

Years Active: 1994-2003

Loading Chart...
14 patents (USPTO):Explore Patents
1. 6541515 - HIV integrase inhibitors (2003-04-01),
2. 6403347 - HIV integrase inhibitors (2002-06-11),
3. 6124327 - HIV integrase inhibitors (2000-09-26),
4. 6110716 - HIV integrase inhibitors (2000-08-29),
5. 5858738 - Ermophilane sesquiterpenoids as HIV intergrase inhibitors (1999-01-12),
6. 5789438 - Inhibitors of farnesyl-protein transferase (1998-08-04),
7. 5703067 - Inhibitors of farnesyl-protein transferase (1997-12-30),
8. 5663193 - Inhibitors of farnesyl-protein transferase (1997-09-02),
9. 5627057 - Inhibitor compounds of farnesyl-protein transferase and chemotherapeutic (1997-05-06),
10. 5510371 - Inhibitors of farnesyl-protein transferase (1996-04-23),
11. 5436263 - Inhibitors of farnesyl-protein transferase (1995-07-25),
12. 5420334 - Inhibitors of farnesyl-protein transferase (1995-05-30),
13. 5420157 - Inhibitors of farnesyl protein transferase or prodrugs thereof (1995-05-30),
14. 5283256 - Cholesterol-lowering agents (1994-02-01),

Title: **Innovator in Viral Therapeutics: The Contributions of Keith C. Silverman**

Introduction

Keith C. Silverman, an accomplished inventor based in Somerset, NJ, is renowned for his significant contributions to the field of viral therapeutics. With a portfolio of 14 patents, he has been instrumental in advancing the treatment and prevention of HIV/AIDS. His innovative work continues to change lives and shape the landscape of antiviral research.

Latest Patents

Among his recent patents, Silverman has developed HIV integrase inhibitors that showcase compounds useful for inhibiting HIV integrase. These compounds play a crucial role in the prevention or treatment of HIV infections and AIDS. They are presented as pharmaceutically acceptable salts and pharmaceutical composition ingredients, whether administered alone or in conjunction with other antivirals, immunomodulators, antibiotics, or vaccines. The patents also describe methods for treating AIDS and outline processes for creating these compounds using the culture Cytospora sp. MF 6608 (ATCC PTA-1691). Additionally, natural products such as certain chaetochromins are noted for their potential utility in inhibiting HIV integrase and contributing to AIDS treatment strategies.

Career Highlights

Silverman's innovative journey includes his association with Merck & Company, Inc., where he has significantly impacted antiviral research. His dedication to developing effective treatments for HIV/AIDS has garnered acknowledgment in both academia and industry. His work exemplifies the intersection of scientific research and practical application, leading to real-world benefits for patients.

Collaborations

Throughout his career, Keith has collaborated with prolific researchers including Russell B. Lingham and Sheo B. Singh. These partnerships have facilitated enhanced research initiatives and have driven forward innovations in virology and antiviral therapy, further amplifying the impact of their collective expertise.

Conclusion

Keith C. Silverman's contributions to antiviral research soar above conventional boundaries. His latest innovations in HIV integrase inhibitors reflect a commitment to scientific excellence and the betterment of healthcare solutions. As he continues to explore new frontiers in viral therapeutics, his work embodies the spirit of innovation that is essential for addressing some of today's most pressing health challenges.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…